A prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban vs. VKA in subjects undergoing catheter ablation of non-valvular atrial fibrillation (ELIMINATE-AF)
A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal.
Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)
A phase 3, placebo controlled, double-blind, randomized, clinical study to determine the efficacy, safety and tolerability of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial hypertension (PAH): INOvation-1
A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent acute coronary syndrome (ACS): The dal-GenE trial
The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study